Applicability of supercritical fluid chromatography for oligonucleotide analysis: A proof-of-concept study.

Enhanced fluidity liquid chromatography Nucleic acid Oligonucleotide Supercritical fluid chromatography Unified chromatography

Journal

Journal of chromatography. A
ISSN: 1873-3778
Titre abrégé: J Chromatogr A
Pays: Netherlands
ID NLM: 9318488

Informations de publication

Date de publication:
11 Oct 2023
Historique:
received: 18 06 2023
revised: 10 08 2023
accepted: 24 08 2023
medline: 25 9 2023
pubmed: 4 9 2023
entrez: 3 9 2023
Statut: ppublish

Résumé

We evaluated the suitability of supercritical fluid chromatography (SFC) for oligonucleotide analysis using 4-mer oligonucleotides with various phosphorothioate (PS) contents as model compounds. Column screening showed that the diol-modified column was able to separate sequences with different PS contents. Optimization of the column body and additives allowed us to analyze polar oligonucleotides using SFC. Various sequences were also analyzed using the optimized method. A good peak shape was obtained when the guanine plus cytosine content of the analyte was two or less in the 4-mer oligonucleotides. Furthermore, we found that the retention times of the selected sequences were positively correlated with polar surface areas, indicating that oligonucleotides interact with polar stationary phases. In contrast, more hydrophobic full PS sequences were retained more strongly in the diol column than the full phosphodiester (PO) sequences. This suggests that the diol column has unique selectivity for PO and PS linkages. These results indicate that SFC is potentially applicable to oligonucleotide analysis with a separation mechanism that is different from that of ion-pair reversed-phase liquid chromatography.

Identifiants

pubmed: 37660558
pii: S0021-9673(23)00558-7
doi: 10.1016/j.chroma.2023.464333
pii:
doi:

Substances chimiques

thiophosphoric acid TYM4M7EWCW
Oligonucleotides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

464333

Informations de copyright

Copyright © 2023. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Momoka Hayashida (M)

Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan; Shimadzu Analytical Innovation Research Laboratories, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan; Shimadzu Corporation, 1 Nishinokyo Kuwabara-cho, Nakagyo-ku, Kyoto 604-8511, Japan.

Risa Suzuki (R)

Shimadzu Corporation, 1 Nishinokyo Kuwabara-cho, Nakagyo-ku, Kyoto 604-8511, Japan.

Shinnosuke Horie (S)

Shimadzu Analytical Innovation Research Laboratories, 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan; Shimadzu Corporation, 1 Nishinokyo Kuwabara-cho, Nakagyo-ku, Kyoto 604-8511, Japan; Shimadzu Europa GmbH, Albert-Hahn-Strasse 6-10, Duisburg 47269, Federal Republic of Germany.

Junichi Masuda (J)

Shimadzu Corporation, 1 Nishinokyo Kuwabara-cho, Nakagyo-ku, Kyoto 604-8511, Japan.

Takao Yamaguchi (T)

Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. Electronic address: yamaguchi-ta@phs.osaka-u.ac.jp.

Satoshi Obika (S)

Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. Electronic address: obika@phs.osaka-u.ac.jp.

Articles similaires

Humans Hip Fractures Female Male Aged, 80 and over
Humans Ceftriaxone Rivaroxaban Chromatography, High Pressure Liquid Acetaminophen
Humans Adolescent Female Male Phenotype
Humans Pilot Projects Artificial Intelligence Natural Language Processing Clinical Trials, Phase I as Topic

Classifications MeSH